Effect of spironolactone, potassium canrenoate and their common metabolite canrenone on serum digoxin measurement by digoxin III, a new digoxin immunoassay

Therapeutic Drug Monitoring

Volumn 30, Issue 6, 2008, Pages 744-747

  Dasgupta, Amitava ^a   Tso, Gertie ^b   Wells, Alice ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b MEMORIAL HERMANN HOSPITAL   (United States)

Author keywords

Digoxin III; Digoxin immunoassay; Interference; Metabolite; Spironolactone; Tina quant

Indexed keywords

CANRENOATE POTASSIUM; CANRENONE; DIGOXIN; SPIRONOLACTONE;

ARTICLE; CONTROLLED STUDY; CROSS REACTION; DIGOXIN BLOOD LEVEL; DIGOXIN III IMMUNOASSAY; DRUG DETERMINATION; DRUG EFFECT; HUMAN; IMMUNOASSAY; INTERMETHOD COMPARISON; PRIORITY JOURNAL; TINA QUANT ASSAY;

ALDOSTERONE ANTAGONISTS; CANRENOATE POTASSIUM; CANRENONE; CROSS REACTIONS; DIGOXIN; DRUG INTERACTIONS; HUMANS; IMMUNOASSAY; SPIRONOLACTONE;

EID: 57749122304     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/FTD.0b013e31818b0e6a     Document Type: Article

References (28)

1. Cook CS, Hauswald CL, Schoenhard GL, et al. Difference in metabolic profile of potassium canrenoate and spironolactone in rat: mutagenic metabolites unique to potassium canrenoate. Arch Toxicol. 1988;61: 201-212.
2. Kojima K, Yamamoto K, Fujioka H, et al. Pharmacokinetics of spironolactone and potassium canrenoate in humans. J Pharmacobiodyn. 1985;8:161-166.
3. Vose CW, Boreham DR, Ford GC, et al. Identification of some human urinary metabolites of orally administered potassium canrenoate by stable isotope labeling techniques. Drug Metab Dispos. 1979;7:226-232.
4. Rea TD, Siscovick DS, Psaty BM, et al. Digoxin therapy and risk of primary cardiac arrest in patients with congestive heart failure: effect of mild-moderate renal impairment. J Clin Epidemiol. 2003;56;646-650.
5. Adams KF, Patterson JH, Gattis WA, et al. Relationship of serum digoxin concentrations to mortality and morbidity in women in the digitalis investigation group trial: a retrospective study. J Am Coll Cardiol. 2005;46:497-504.
6. Huffman DH. The effects of spironolactone and canrenone in digoxin radioimmunoassay. Res Commun Chem Pathol Pharmacol. 1974;9: 787-790.
7. Crothers DC. Interference of spironolactone metabolites in a digoxin radioimmunoassay [Letter]. Ther Drug Monit. 1989;11:113-114.
8. Lichey J, Schroder R, Rietbrock N. The effect of oral spironolactone and intravenous canrenoate K on the digoxin radioimmunoassay. Int J Clin Pharmacol Biopharm. 1977;15:557-559.
9. Lichey J, Rietrock N, Borner K. The influence of intravenous canrenoate on the determination of digoxin in serum by radio and enzyme immunoassay. Int J Clin Pharmacol Biopharm. 1979;17:61-63.
10. Silber B, Sheiner LB, Powers JL, et al. Spironolactone-associated digoxin radioimmunoassay interference. Clin Chem. 1979;25:48-50.
11. Morris RG, Frewin DB, Taylor WB, et al. The effect of renal and hepatic impairment and of spironolactone on serum digoxin assay. Eur J Clin Pharmacol. 1988;34:233-239.
12. Pleasants RA, Williams DM, Porter RS, et al. Reassessment of cross-reactivity of spironolactone metabolites with four digoxin assays. Ther Drug Monit. 1989;11: 200-204.
13. Foukaridis GN. Influence of spironolactone and its metabolite canrenone on serum digoxin assays. Ther Drug Monit. 1990;12:82-84.
14. Stone JA, Soldin SJ. An update on digoxin. Clin Chem. 1989;35: 1326-1331.
15. Okazaki M, Tanigawara Y, Kita T, et al. Cross-reactivity of TDX and OPUS immunoassay system for serum digoxin determination. Ther Drug Monit. 1997;19:657-662.
16. Steimer W, Muller C, Eber B, et al. Intoxication due to negative canrenone interference in digoxin monitoring [Letter]. Lancet. 1999;354:1176-1177.
17. Steimer W, Muller C, Eber B. Digoxin assays: frequent, substantial, and potentially dangerous interference by spironolactone, canrenone and other steroids. Clin Chem. 2002;48:507-516.
18. Dasgupta A, Saffer H, Wells A, et al. Bidirectional (positive/negative) interference of spironolactone, canrenone and potassium canrenoate on serum digoxin measurement: elimination of interference by measuring free digoxin or using a chemiluminescent assay for digoxin. J Clin Lab Anal. 2002;16:172-177.
19. Tal DM. 6,7-dihydroxy-6,7-dihydrocanrenone isomers: improved synthesis and proton NMR study. Steroids. 1989;54:113-122.
20. Shenfield GM, Morris RG. Therapeutic drug monitoring. Curr Opin Anaesthesiol. 2002;15:687-692.
21. Craver JL, Valdes R. Anomalous serum digoxin concentration in uremia. Ann Intern Med. 1983;98:483-484.
22. Miller JJ, Straub RW, Valdes R Jr. Analytical performance of a monoclonal digoxin assay with increased specificity on the ACS:180. Ther Drug Monit. 1996;18:65-72.
23. Jortani SA, Valdes R Jr. Digoxin and its related endogenous factors. Crit Rev Clin Lab Sci 1997;34: 225-274.
24. Qazzaz HM, Valdes R Jr. Simultaneous isolation of endogenous digoxin-like immunoreactive factor, ouabain-like factor, and deglycosylated congeners from mammalian tissue. Arch Biochem Biophys. 1996;328: 193-200.
25. Qazzaz HM, Cao Z, Bilanowski DD, et al. De novo biosynthesis and radiolabeling of mammalian digitalis like factors. Clin Chem. 2004;50: 612-620.
26. Morris RG, Jones TE, Goldsworthy SJ, et al. Suspected DLIS interference in the dimension DGNA digoxin assay method and clinical application of the revised digoxin target range. Ther Drug Monit. 2006;28: 454-457.
27. Gardiner P, Schrode K, Quinlan D, et al. Spironolactone metabolism: steady state serum levels of the sulfur containing metabolites. J Clin Pharmacol. 1989;29:342-347.
28. Karras K, Seifert W. Pharmacokinetics of canrenone after oral administration of spironolactone and intravenous injection of canrenoate-K in healthy man. Eur J Clin Pharmacol. 1983;25:449-453.